目前,随着越来越多肿瘤靶向药物和免疫药物的获批上市,基因检测已经逐渐成为肿瘤治疗的常规手段。单一基 因的检测已经无法满足临床检测需求,多基因平行检测可以助力发现更多指导临床用药的基因变异类型。燃石医 学拥有完善的产品线,全面覆盖各实体瘤的药物伴随诊断和微小分子残留检测,全周期护航患者精准医疗。

查看更多

生物标志物检测和伴随诊断开发已成为精准治疗与肿瘤药物研发的重要组成部分。从药物发现到临床试验甚至上市后研究,都伴随着生物标志物的发现、验证、用于指导患者分层和疗效分析等。燃石医学聚焦于癌症全周期,从生物标志物发现到商业化为生物制药公司提供肿瘤基因组学解决方案,高效助力肿瘤药物开发全流程。

查看更多

癌症是威胁人类健康的重大公共卫生问题。80%的中国癌症患者发现即中晚期,给家庭和社会带来了沉重的经济负担。随着人口老龄化的增加,肿瘤防治领域面临越来越严峻的挑战。早发现早治疗是降低癌症死亡率的有效途径,燃石医学已经在多癌种早检技术领域取得关键突破,将优秀的创新技术加速引入临床,以先进、优质的产品和服务为国民健康保驾护航。

查看更多

燃石医学和礼来达成伴随诊断合作意向,助力中国肿瘤精准诊疗新发展

发布日期:2022-11-09

2022年11月6日,燃石医学与礼来达成伴随诊断合作意向。双方将整合各方在肿瘤诊断和治疗领域的优势资源,围绕患者全病程管理需求,共...

查看更多

聚力同心,肺癌少见靶点生态联盟签约成立

发布日期:2022-11-09

2022年11月6日,罗氏制药携手燃石医学等7家公司在第五届中国国际进口博览会期间签约成立“肺癌少见靶点生态联盟”,各方将在提高肺...

查看更多

  • 学术合作

    CTONG共建NGS实验室的首家合作伙伴
  • 检测平台

    占全球测序市场份额80%的IIIumina在中国的临床肿瘤战略合作伙伴,与IIIumina启动Miseq dx测序仪联合临床实验
  • 分子诊断解决方案

    燃石医学将在中国开发基于Agilent SureSelect 靶向序列捕获系统的肿瘤基因检测,为中国肿瘤患者提供更多高品质的基于二代基因测序的分子诊断解决方案
  • 学术合作

    搭建分享、讨论真实世界精准诊疗病例的平台,共同探索未知,推进精准诊疗实践。
  • 学术合作

    CSCO CAGC肺癌研究指定检测合作伙伴
  • 分子诊断解决方案

    凯杰(QIAGEN)中国在液体活检领域战略合作伙伴,保证燃石ctDNA样本制备技术和产品质量的可靠
  • 精准用药

    阿斯利康肺癌NGS检测唯一战略伙伴,代表NGS方法学参与ASTRIS研究,参与L-moca奥拉帕利中国四期临床研究(HRD)

At present, with more and more tumor targeted drugs and immune drugs approved for marketing and even included in medical insurance, genetic testing has gradually become a routine means of cancer treatment. Based on the....

More

As medicine is booming and people go deeper in understanding the molecular mechanism for cancers, cancer treatment has evolved step by step from pregenome-based cytotoxic drug therapy to genome-based targeted therapy with .....

More

Research and development of cancer drug has embarked on a precision era. In this era, the progress in molecular oncology and genomics indicates a new challenge and opportunity in research and development of targeted ...

More

Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detecti...;

Var Date:2022-05-20

Burning Rock announced that it has received CE marking for its Ov...

More

Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits ;

Var Date:2022-05-07

Burning Rock announced that the Company had received CE mark appr...

More

  • Academic Cooperation

    CTONG's First Partner for Founding NGS Lab
  • Detection Platform

    Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection.
  • Molecular Diagnostics Solutions

    Burning Rock Dx is planning to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients
  • Academic Cooperation

    For building a platform for sharing and discussing precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice.
  • Academic Cooperation

    Designated testing partner to CSCO and CAGC in lung cancer research
  • Molecular Diagnostics Solutions

    Burning Rock’s reassuring strategic partner in liquid biopsy - QIAGEN China with ctDNA sample preparation technology and high product quality
  • Precision Medicine

    AstraZeneca's sole strategic NGS lung cancer testing partner involved in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD) in China